Machine learning (ML) has become a crucial component of early drug discovery. This research area has been fueled by two main factors. The first is the fast-growing availability of relevant experimental data. Examples of such datasets are those containing the bioactivities of molecules of known chemical structure against a non-molecular target (e.g., a cancer cell line), binding affinities of such molecules against a molecular target (e.g., a particular kinase validated for a specific cancer type) or the X-ray crystal structures of a molecular target. This factor has been boosted by the development of community resources, such as ChEMBL PDBbind [4], that curate and facilitate re-using these datasets for predictive modelling. The second factor is the easy access to high-quality and well-documented implementations of a range of ML algorithms, including those of recent advances such as XGBoost [5] , deep learning [6], or conformal prediction [7] . As a result, an increasing number of data-driven ML models have been proposed and found advantageous in some way in identifying new starting points for the drug discovery process. This Special Issue showcases five studies investigating the application of ML for molecular modelling in drug design. These studies have been carried out by 21 academic and industry researchers from around the World. ML techniques include support vector machines (SVM), random forest (RF), k-nearest neighbors (k-NN), convolutional neural network (CNN), or recurrent neural network (RNN), either alone or integrated with dimensionality reduction techniques such as GA(genetic algorithm)-based feature selection (FS) and principal component analysis (PCA).
concluded that it was possible to predict this type of mutagenicity in an independent set of compounds while estimating the errors of each of these individual predictions using their methodology.
Bjerrum and Sattarov [11] demonstrated that the QSAR model accuracy can be improved by using heteroencoders of the molecules as features. The common approach of using autoencoders on canonical simplified molecular-input line-entry system (SMILES) is hampered by their poor neighborhood behavior (i.e., similar chemical structures mapping onto dissimilar canonical SMILES). A heteroencoder is introduced as an autoencoder considering several non-canonical SMILES as input, instead of a single canonical SMILES, for each molecule to factor in the impact of different chemical representations on modelling. These heteroencoders were trained using CNNs and RNNs with long short-term memory cells. In comparison to using autoencoders, the use of heteroencoders resulted in better predictive performance of the resulting QSAR models. Furthermore, the spanned latent space led to a better agreement between SMILES similarity and circular fingerprint similarity of the considered molecules.
Machine learning has been used to generate diverse ligand-based predictive models in these four contributions so far [8] [9] [10] [11] by exploiting chemical structure and bioactivity data. However, by also exploiting X-ray crystal structure data, ML can also be used to build protein-ligand predictive models. These models are known as ML scoring functions (SFs) and have been found to be an important complement to classical SFs in docking [12] . The last paper in this issue [13] investigated whether the well-known superiority of ML SFs over classical SFs on average across targets is exclusively due to the presence of training complexes with highly similar proteins to those in the test set. We addressed this question by using 24 similarity-based training sets, a widely used test set, and four SFs. We found that an RF-based SF outperforms the best classical SF even when 68% of the most similar proteins are removed from the training set. In addition, unlike the classical SF, the RF-based SF is able to keep learning as the training set size grows, becoming substantially more predictive when the full 1105 data instances are used for training. These results show that ML SFs owe a substantial part of their performance to training on complexes with dissimilar proteins to those in the test set.
